234 related articles for article (PubMed ID: 34725361)
1. The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors.
Gebregiworgis T; Kano Y; St-Germain J; Radulovich N; Udaskin ML; Mentes A; Huang R; Poon BPK; He W; Valencia-Sama I; Robinson CM; Huestis M; Miao J; Yeh JJ; Zhang ZY; Irwin MS; Lee JE; Tsao MS; Raught B; Marshall CB; Ohh M; Ikura M
Nat Commun; 2021 Nov; 12(1):6274. PubMed ID: 34725361
[TBL] [Abstract][Full Text] [Related]
2. The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS.
Li C; Vides A; Kim D; Xue JY; Zhao Y; Lito P
Science; 2021 Oct; 374(6564):197-201. PubMed ID: 34618566
[TBL] [Abstract][Full Text] [Related]
3. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.
Wong GS; Zhou J; Liu JB; Wu Z; Xu X; Li T; Xu D; Schumacher SE; Puschhof J; McFarland J; Zou C; Dulak A; Henderson L; Xu P; O'Day E; Rendak R; Liao WL; Cecchi F; Hembrough T; Schwartz S; Szeto C; Rustgi AK; Wong KK; Diehl JA; Jensen K; Graziano F; Ruzzo A; Fereshetian S; Mertins P; Carr SA; Beroukhim R; Nakamura K; Oki E; Watanabe M; Baba H; Imamura Y; Catenacci D; Bass AJ
Nat Med; 2018 Jul; 24(7):968-977. PubMed ID: 29808010
[TBL] [Abstract][Full Text] [Related]
4. Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors.
Sahu P; Mitra A; Ganguly A
Int Rev Cell Mol Biol; 2024; 386():167-222. PubMed ID: 38782499
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer.
Lo A; McSharry M; Berger AH
BMC Cancer; 2022 Dec; 22(1):1315. PubMed ID: 36522653
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition.
Wei W; Geer MJ; Guo X; Dolgalev I; Sanjana NE; Neel BG
J Exp Med; 2023 May; 220(5):. PubMed ID: 36820830
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant Cancers.
Hou Q; Jiang W; Li W; Huang C; Yang K; Chen X; Huang M; Shu C; Luo G; Sun H; Chu Q; Wu X
J Med Chem; 2023 Oct; 66(19):13646-13664. PubMed ID: 37754066
[TBL] [Abstract][Full Text] [Related]
8. Functional and biological heterogeneity of KRAS
Huynh MV; Hobbs GA; Schaefer A; Pierobon M; Carey LM; Diehl JN; DeLiberty JM; Thurman RD; Cooke AR; Goodwin CM; Cook JH; Lin L; Waters AM; Rashid NU; Petricoin EF; Campbell SL; Haigis KM; Simeone DM; Lyssiotis CA; Cox AD; Der CJ
Sci Signal; 2022 Aug; 15(746):eabn2694. PubMed ID: 35944066
[TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanism of Phosphorylation-Mediated Impacts on the Conformation Dynamics of GTP-Bound KRAS Probed by GaMD Trajectory-Based Deep Learning.
Chen J; Wang J; Yang W; Zhao L; Zhao J; Hu G
Molecules; 2024 May; 29(10):. PubMed ID: 38792177
[TBL] [Abstract][Full Text] [Related]
10. Q61 mutant-mediated dynamics changes of the GTP-KRAS complex probed by Gaussian accelerated molecular dynamics and free energy landscapes.
Chen J; Zeng Q; Wang W; Hu Q; Bao H
RSC Adv; 2022 Jan; 12(3):1742-1757. PubMed ID: 35425180
[TBL] [Abstract][Full Text] [Related]
11. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
[TBL] [Abstract][Full Text] [Related]
12. Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization.
Xu Z; Guo C; Ye Q; Shi Y; Sun Y; Zhang J; Huang J; Huang Y; Zeng C; Zhang X; Ke Y; Cheng H
Nat Commun; 2021 Nov; 12(1):6310. PubMed ID: 34728626
[TBL] [Abstract][Full Text] [Related]
13. Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors.
Xu X; Masubuchi T; Cai Q; Zhao Y; Hui E
Elife; 2021 Nov; 10():. PubMed ID: 34734802
[TBL] [Abstract][Full Text] [Related]
14. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
[TBL] [Abstract][Full Text] [Related]
15. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment.
Chen WS; Liang Y; Zong M; Liu JJ; Kaneko K; Hanley KL; Zhang K; Feng GS
Cell Rep; 2021 Nov; 37(6):109974. PubMed ID: 34758313
[TBL] [Abstract][Full Text] [Related]
16. Cancer cell-derived exosomal circUSP7 induces CD8
Chen SW; Zhu SQ; Pei X; Qiu BQ; Xiong D; Long X; Lin K; Lu F; Xu JJ; Wu YB
Mol Cancer; 2021 Nov; 20(1):144. PubMed ID: 34753486
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models.
Nakayama A; Nagashima T; Nishizono Y; Kuramoto K; Mori K; Homboh K; Yuri M; Shimazaki M
Br J Cancer; 2022 Mar; 126(5):744-753. PubMed ID: 34795410
[TBL] [Abstract][Full Text] [Related]
18. Spatially resolved transcriptomics reveals the architecture of the tumor-microenvironment interface.
Hunter MV; Moncada R; Weiss JM; Yanai I; White RM
Nat Commun; 2021 Nov; 12(1):6278. PubMed ID: 34725363
[TBL] [Abstract][Full Text] [Related]
19. Targeting KRAS G12D Mutant for the Potential Treatment of Pancreatic Cancer.
Kargbo RB
ACS Med Chem Lett; 2021 Nov; 12(11):1643-1645. PubMed ID: 34795853
[No Abstract] [Full Text] [Related]
20. Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1.
Shin DH; Kim SH; Choi M; Bae YK; Han C; Choi BK; Kim SS; Han JY
Oncogene; 2022 Jan; 41(2):280-292. PubMed ID: 34743207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
